Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Ocular side effects of drugs used in the treatment of multiple sclerosis.
Acute Disseminated Encephalomyelitis Presenting with Hypertensive Emergency.
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
Impact of Armodafinil on Cognition in Multiple Sclerosis: A Randomized, Double-blind Crossover Pilot Study.
Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod.
Role of TRIF Small Interference RNA (siRNA) in Chronic Experimental Allergic Encephalomyelitis (EAE).
Oral corticosteroids for multiple sclerosis relapse.
Risk Knowledge in Relapsing Multiple Sclerosis (RIKNO 1.0) - Development of an Outcome Instrument for Educational Interventions.
Rosuvastatin enhances anti-inflammatory and inhibits pro-inflammatory functions in cultured microglial cells.
PERK-opathies: an endoplasmic reticulum stress mechanism underlying neurodegeneration.
Cognitive Impairments in Multiple SclerosisImplications for Rehabilitation.
Physiological variation of retinal layer thickness is not caused by hydration: A randomised trial.
Biomarkers of interferon Beta therapy in multiple sclerosis.
The safety of influenza vaccines in children: An Institute for Vaccine Safety white paper.
Ozanimod: a better or just another S1P receptor modulator?
The effect of triiodothyronine on maturation and differentiation of oligodendrocyte progenitor cells during remyelination following induced demyelination in male albino rat.
Advanced MRI unravels the nature of tissue alterations in early multiple sclerosis.
Hesperidin, a Citrus Flavonoid, Has the Ameliorative Effects Against Experimental Autoimmune Encephalomyelitis (EAE) in a C57BL/J6 Mouse Model.
Epigenetics in autoimmune diseases: Pathogenesis and prospects for therapy.
Prolactin: A versatile regulator of inflammation and autoimmune pathology.
[Two new oral disease modifying therapies in relapsing remitting multiple sclerosis].
Network collapse and cognitive impairment in multiple sclerosis.
Varicella-zoster virus encephalomyelitis with a prominent demyelinating component.
Molecular genetic studies of multiple sclerosis in the portuguese population.
The Use of Focus Groups to Characterize Symptoms in Persons With Multiple Sclerosis.
Pages
« first
‹ previous
…
500
501
502
503
504
505
506
507
508
…
next ›
last »